Outcomes of allogeneic hematopoietic stem cell transplantation for ATL with HTLV-1 antibody positive donors

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only treatment option achieving long-term remission for patients with aggressive adult T cell leukemia –lymphoma (ATL)1,2. A recent meta-analysis showed that the pooled overall survival (OS) and relapse and non-relapse mortality rates were 40% [95% confidence interval (CI): 33‒46%), 36% (95%CI: 28‒43%), and 29% (95%CI: 21‒37%), respectively3. Previous studies reported that better pretranspla nt disease status4-7, fewer comorbidities8, and earlier transplantation9 are the most important factors in predicting allo-HCT success.

Source: Biology of Blood and Marrow Transplantation - December 6, 2019 Category: Hematology Authors: Makoto Yoshimitsu, Shigeo Fuji, Atae Utsunomiya, Nobuaki Nakano, Ayumu Ito, Yoshikiyo Ito, Toshihiro Miyamoto, Youko Suehiro, Toshiro Kawakita, Yukiyoshi Moriuchi, Hirohisa Nakamae, Yoshinobu Kanda, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Koji K Source Type: research